Mode
Text Size
Log in / Sign up

MR relaxometry identifies temporomesial abnormalities in systemic sclerosis with limbic encephalitis not seen on standard imagingAdvanced imaging reveals hidden brain changes in systemic sclerosis patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that MR relaxometry may detect temporomesial abnormalities in systemic sclerosis not visible on standard MRI.

This case report describes a 58-year-old man with systemic sclerosis and limbic encephalitis presenting with subacute cognitive impairment and dialeptic seizures. The report details the use of multimodal imaging, including MRI, MR relaxometry, MR spectroscopy, and FDG-PET/CT, to evaluate the extent of neurological involvement.

Key findings include enlargement and T2 hyperintensity of the right hippocampus and amygdala on MRI, and focal hypermetabolism of the right amygdala on FDG-PET/CT. Proton MR spectroscopy showed a bilateral reduction of total N-acetylaspartate. Notably, MR relaxometry revealed significant bilateral T2 prolongation in the amygdalae and hippocampal heads, with T1 abnormalities involving the right amygdala and both hippocampal heads. Serum testing also detected anti-pyruvate dehydrogenase antibodies despite negative routine clinical neural antibody testing.

A primary limitation of this evidence is that it is based on a single case report. However, the authors note that MR relaxometry revealed temporomesial abnormalities not apparent on conventional imaging. This suggests that routine imaging protocols may underestimate the extent of disease in patients with systemic sclerosis and limbic encephalitis.

How this fits prior evidence

This case report addresses a gap in the clinical understanding of neuroimaging in systemic sclerosis. While previous coverage noted that intravenous immunoglobulin improves skin and gastrointestinal manifestations in systemic sclerosis, this report focuses on the neurological manifestations and the specific utility of advanced imaging techniques like MR relaxometry to identify extent of involvement.

When a patient with systemic sclerosis experienced memory issues and seizures, doctors used several types of advanced imaging to see what was happening in the brain. They found that while standard scans showed some changes, more specialized techniques revealed much more significant damage in the areas of the brain that control memory and emotion.

These advanced scans, including MR relaxometry, showed significant issues in the amygdala and hippocampus. These are the parts of the brain that help us process emotions and memories. The study also found specific antibodies in the patient's blood that were not caught by routine tests.

Because this was a single case report, we cannot say for certain how common these findings are. However, it suggests that standard imaging might underestimate how much a disease is affecting the brain. Doctors can use these advanced tools to get a clearer picture of the extent of the condition.

What this means for you:
Advanced imaging may reveal brain damage that standard scans miss in patients with systemic sclerosis.

Common questions

What did the advanced imaging show?

Advanced imaging, specifically MR relaxometry, showed significant changes in the amygdala and hippocampus. These are areas of the brain involved in memory and emotion. While standard scans showed some issues, these advanced tools revealed more extensive damage that might otherwise be missed by routine tests.

What symptoms did the patient experience?

The patient, a 58-year-old man with systemic sclerosis, experienced subacute cognitive impairment and dialeptic seizures. These are types of memory issues and seizures that occur in a specific pattern. The study also found specific antibodies in his blood.

Is this a common finding for everyone with systemic sclerosis?

Because this was a single case report involving only one patient, we cannot say if these findings are common. It serves as a look at how advanced imaging can provide a more detailed view of the disease than standard scans.

Study Details

Study typeGuideline
EvidenceLevel 5
PublishedSep 2026
View Original Abstract ↓
Central nervous system involvement is uncommon in systemic sclerosis, and inflammatory temporomesial syndromes in this context are rarely reported. We present a 58-year-old man with systemic sclerosis who developed subacute cognitive impairment and dialeptic seizures arising from the right temporal lobe. Video electroencephalography confirmed a right temporal seizure onset zone. Brain magnetic resonance imaging demonstrated enlargement and subtle T2 hyperintensity of the right hippocampus and amygdala, while fluorodeoxyglucose-positron emission tomography/computed tomography images showed focal hypermetabolism of the enlarged right amygdala. Proton magnetic resonance spectroscopy demonstrated bilateral reduction of total N-acetylaspartate compared with an age-matched healthy reference subject, with a more pronounced difference on the right, a pattern compatible with bilateral, right-accentuated neuronal dysfunction or injury. MR relaxometry demonstrated significant bilateral T2 prolongation in the amygdalae and hippocampal heads, whereas T1 abnormalities were more region-dependent, involving the right amygdala and both hippocampal heads. Serum testing detected anti-pyruvate dehydrogenase antibodies, whereas routine clinical neural antibody testing was negative. The patient became seizure-free under antiseizure medication and immunosuppressive therapy with cyclophosphamide. Notably, although the unilateral conventional imaging findings did not meet the bilateral mesial temporal criterion required by current consensus criteria for definite autoimmune limbic encephalitis, MR relaxometry revealed bilateral temporomesial abnormalities. This finding is consistent with available neuropathological and experimental evidence and suggests that routine imaging may underestimate disease extent. This case highlights a rare presentation of antibody-atypical limbic encephalitis in the setting of systemic sclerosis and illustrates how multimodal imaging can support diagnosis and tissue characterization when routine antibody testing is unrevealing.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.